MaxCyte, Inc. - Common Stock (MXCT)

Management sees its Akron Bio deal accelerating the path to profitability ahead.

MaxCyte (NASDAQ:MXCT) reported 49% third-quarter revenue growth and raised its 2026 revenue outlook, while announcing an agreement to acquire cell therapy materials supplier Akron Bio for $151.8 million. The transaction, which has not yet closed, is expected to nearly double MaxCyte’s revenue base

Revenue declined 15% year-over-year, but net losses narrowed significantly.

MaxCyte (NASDAQ:MXCT) reported second-quarter 2026 revenue of $7.3 million, down 15% from $8.5 million a year earlier, as lower license revenue, timing of instrument placements and prior-year processing assembly purchases affected results. Management said the quarter came in ahead of its expectation

MaxCyte (NASDAQ:MXCT) reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the declin

MaxCyte (MXCT) Q4 2025 Earnings Call Transcript

Stay up-to-date with the latest market trends one hour before the close of the markets on Thursday. Explore the top gainers and losers during today's session in our detailed report.

Wondering how the US markets performed in the middle of the day on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's have a look at the gap up and gap down stocks in today's session.